CTNI is the first center worldwide combining magnetic resonance imaging and molecular imaging in awake animals:
- Proprietary technology for identifying new atypical antipsychotics
- Proprietary technology for assessing toxicity and risk to chronic CNS drug exposure
- Proprietary technology for imaging fully conscious animals for usein MR, SPECT and PET
- Custom SPECT and PET radiolabeling of drug candidates for evaluation of pharmacokinetics, site of action and dose occupancy in fully conscious animals
- Custom chemical synthesis and radiolabeling for both the development of biomarkers for disease diagnosis and prospective studies on drug efficacy Translational imaging using transgenic mice, inbred strains of rats and marmoset monkeys
- Expertise in assessing pharmaco-kinetics and pharmaco-dynamics of novel therapies in vivo using nuclear imaging techniques (PET, SPECT and CT). Established protocols in cardiac, oncology and CNS applications. Significant experience in performing large-scale imaging studies on xenograft models evaluating interaction of therapeutics across a variety of imaging agents. In vivo and ex vivo correlation of biomarkers such as cellular/molecular assays for proliferation, apoptosis, or histopathology.